438492-38-7

Basic information

• Product Name: Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate
• Synonyms: Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate;Methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate
• CAS NO: 438492-38-7
• Molecular Formula: C20H23NO3
• Molecular Weight: 325.4
• Mol File: 438492-38-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate(438492-38-7)
• EPA Substance Registry System: Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate(438492-38-7)

Safety Data

• Hazardous Substances Data: 438492-38-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate is utilized as a precursor in the synthesis of a variety of drugs and chemical compounds. Its unique structure allows it to be a key component in the development of new medications.
Used in Research and Development:
In the realm of research and development, trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate serves as an important tool for the exploration and creation of novel organic synthesis pathways and potential therapeutic agents.
Used in the Treatment of Neurological and Psychiatric Disorders:
Trans-methyl 1-benzyl-4-(4-methoxyphenyl)pyrrolidine-3-carboxylate has been studied for its potential therapeutic properties, particularly in addressing neurological and psychiatric disorders. Its role in this area highlights the compound's significance in medicinal chemistry and drug discovery.

Upstream product

• 3901-07-3 3-(4-methoxy-phenyl)acrylic acid methyl ester 
• 65950-40-5 N,N-bis(tosylmethyl)benzylamine 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 118938-43-5 C₁₀H₉FO₂ 

Downstream Products

• 1186654-76-1 (+/-)-trans-tert-butyl 3-(hydroxymethyl)-4-(4-methoxyphenyl)-pyrrolidine-1-carboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

1,3-Dipolar cycloaddition of unstabilised azomethine ylides by Lewis base catalysis

Lewis base catalysed 1,3-dipolar cycloaddition between α,β- unsaturated acyl fluorides and N-[(trimethylsilyl)methyl]amino ethers has been achieved using 1 mol% DMAP. Competition experiments and 19F-NMR studies indicate that the cycloaddition o

QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS

The invention is directed to quinazoline compounds that can inhibit the bioactivity of one or more kinase enzymes, including a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Fit kinase, an Aurora kinase, or a Src kinase, or any combination thereof; to methods of use of those compounds; and to methods of preparation of those compounds. The inventive compounds can be used in the treatment of malconditions including cardiovascular disease, neurogenic pain, hypertension, atherosclerosis, angina, stroke, arterial obstruction, peripheral arterial disease, erectile dysfunction, acute and chronic pain, dementia, Alzheimer's disease, Parkinson's disease, neuronal degeneration, asthma, amyotrophic lateral sclerosis, spinal cord injury, rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, cerebral vasospasm, open angle glaucoma, multiple sclerosis, pulmonary hypertension, acute respiratory distress syndrome, inflammation, diabetes, urinary organ diseases and benign prostatic hypertrophy (BPH), metastasis, cancer, glaucoma, ocular hypertension, retinopathy, autoimmune disease, viral infection, or myocardial pathology.

Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: Discovery of the dihydropyridazinone motif

Optimization of the biological activity of a new class of non-peptidyl, pyridazinone derived human melanocortin subtype-4 receptor agonists is disclosed.

The convenient synthesis of 3-alkyloxycarbonylpyrrolidine derivatives

A series of 3-alkyloxycarbonylpyrrolidine derivatives are readily achieved via 1,3-dipolar cycloaddition of α,β-unsaturated esters with nonstabilized azomethine ylides in the presence of samarium diiodide.